BMY250110P45000
- 0.00
- 0.000.00%
Bristol-Myers Squibb Newsroom
Express News | Light Horse: Financing Led by Versant Ventures and Included Mubadala Capital, Bristol-Myers, Taiho Ventures, and Abbvie
Express News | Light Horse Therapeutics Debuts With $62 Mln Series a Financing
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
San Francisco Police Cancel Time Off as Healthcare Executives Descend -- Barrons.com
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?
Oak Tree Capital's Marks: New things are prone to bubbles, currently private equity buying S&P 500, with a 10-year yield of only ±2%.
Max recently released a memorandum titled "Revisiting the Bubble," stating that investors are currently betting on the leading high-tech companies to maintain their dominance. However, he believes that it is not easy to stay ahead, as new technologies and competitors can surpass existing market leaders at any time. When people assume that "things can only get better" and Buy based on that, the impact of negative news can be particularly severe. He specifically pointed out the frenzy over AI and how this positive sentiment may spread to other Technology sectors.
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Truist Securities Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $65
Bristol-Myers Squibb Analyst Ratings
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Announces Target Price $65
Bristol Late-stage Trial of Opdivo for Head and Neck Cancer Meets Endpoint
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Should Bristol-Myers Squibb Company (NYSE:BMY) Be In Your Early Retirement Portfolio?
Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Express News | Bristol-Myers Squibb Co -Preliminary Estimated Q4 Impact of Acquired in-Process Research and Development and Licensing Loss of $18 Mln
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference
Bristol-Myers Squibb Options Spot-On: On January 2nd, 391.89K Contracts Were Traded, With 617.52K Open Interest
On January 2nd ET, $Bristol-Myers Squibb(BMY.US)$ had active options trading, with a total trading volume of 391.89K options for the day, of which put options accounted for 1.2% of the total